Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00DYK
|
|||
| Former ID |
DIB009141
|
|||
| Drug Name |
Lunacalcipol
|
|||
| Synonyms |
CTA-018; MT-2832; Lunacalcipol (intravenous, secondary hyperparathyroidism); Lunacalcipol (intravenous, secondary hyperparathyroidism), Cytochroma; Vitamin D analogs (secondary hyperparathyroidism), Johns Hopkins/Cytochroma; CTA-018 (intravenous, secondary hyperparathyroidism), Cytochroma; CYP24 inhibitors (intravenous, secondary hyperparathyroidism), Johns Hopkins/Cytochroma
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Phase 2 | [1] | |
| Company |
Johns Hopkins University
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H42O4S
|
|||
| Canonical SMILES |
CC(CC=CS(=O)(=O)C(C)(C)C)C1=CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C
|
|||
| InChI |
1S/C28H42O4S/c1-19(9-8-16-33(31,32)27(3,4)5)24-13-14-25-21(10-7-15-28(24,25)6)11-12-22-17-23(29)18-26(30)20(22)2/h8,11-13,16,19,23,25-26,29-30H,2,7,9-10,14-15,17-18H2,1,3-6H3/b16-8+,21-11+,22-12-/t19-,23-,25+,26+,28-/m1/s1
|
|||
| InChIKey |
RFQHCLMGLJGZNV-UXXOMSPDSA-N
|
|||
| CAS Number |
CAS 250384-82-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cytochrome P450 24 (CYP24A1) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Steroid biosynthesis | |||
| Metabolic pathways | ||||
| MicroRNAs in cancer | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Vitamin D metabolism and pathway | |||
| Reactome | Vitamin D (calciferol) metabolism | |||
| WikiPathways | Metapathway biotransformation | |||
| Oxidation by Cytochrome P450 | ||||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Vitamin D Receptor Pathway | ||||
| Metabolism of steroid hormones and vitamin D | ||||
| Phase 1 - Functionalization of compounds | ||||
| Vitamin D Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01453634) Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018). U.S. National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022679) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.